RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines

► OPG-based peptide YR-11 has dual suppressive activity on bone loss and inflammation. ► YR-11 reduced systemic cytokine levels in AIA rats via inhibition of NF-κB activation. ► In vitro and in vivo evidences are presented. ► The novel peptide could be useful as a new therapeutic for rheumatoid arthritis.